Bio-Techne Corp (NASDAQ:TECH) will begin trading ex-dividend on November 13, 2020. The quarterly dividend payment of $ 0.32 per share is scheduled to be paid on November 27, 2020. The dividend yield based on the latest trading day closing price was 0.42 percent. Shareholders who purchased TECH shares prior to the ex-dividend date are eligible for the cash dividend payment.
Dividends History
wpDataTable with provided ID not found!Click Here For More Historical Dividends Of Bio-Techne Corp
Bio-Techne Corp recently reported first quarter financial results on November 5, 2020, before market open, the Minneapolis based company recorded income for the first quarter of $ 1.43 per share, from the revenue of $ 204.20 million. The quarterly earnings extended 34.91 percent while revenues escalated 11.44 percent compared with the same quarter last year.
Street analysts expected Bio-Techne Corp recently reported first quarter financial results on November 5, 2020, before market open, the Minneapolis based company to report income of $ 1.09 per share on revenue of $ 185.03 million for the first quarter. The bottom line results beat street analysts by $ 0.34 or 31.19 percent, at the same time, top line results outshined analysts by $ 19.17 million or 10.36 percent.
Stock Performance
Shares of Bio-Techne Corp traded up $ 6.17 or 2.05 percent on Wednesday, reaching $ 306.45 with volume of 160.00 thousand shares. Bio-Techne Corp has traded high as $ 308.32 and has cracked $ 303.05 on the downward trend
The closing price of $ 306.45, representing a 93.52 % increase from the 52 week low of $ 155.17 and a 5.24 % decrease over the 52 week high of $ 316.87.
The company has a market capital of $ 11.83 billion and is part of the Healthcare sector and Biotechnology industry.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.
